ライフサイエンスコーパス: urticaria

1 rgic urticaria, solar urticaria, or pressure urticaria).

2 rom disease, and 10 with chronic spontaneous urticaria.

3 tic dermographism, cold urticaria, and solar urticaria.

4 body, effectively treats chronic spontaneous urticaria.

5 s (3.9%) had a history of idiopathic chronic urticaria.

6 ssing QOL in pediatric patients with chronic urticaria.

7 activation release mediators responsible for urticaria.

8 (p.C492Y) associated with familial vibratory urticaria.

9 and inactive urticaria, and 7 cases of acute urticaria.

10 rapeutic targets for patients with vibratory urticaria.

11 be useful for assessment of the activity of urticaria.

12 insect venom-, and drug allergy and chronic urticaria.

13 EMA) for the treatment of chronic idiopathic urticaria.

14 atients with antihistamine-resistant chronic urticaria.

15 tic approaches for the different subtypes of urticaria.

16 allergies and particular forms of autoimmune urticaria.

17 nd has shown efficacy in chronic spontaneous urticaria.

18 cond case is a man in his 20s with recurrent urticaria.

19 CT items tested in 508 patients with chronic urticaria.

20 trates are seen in a subset of patients with urticaria.

21 arily mild to moderate allergic rhinitis and urticaria.

22 nd to antihistamines and other treatments of urticaria.

23 n reason for recurrent wheals is spontaneous urticaria.

24 ent of severe asthma and chronic spontaneous urticaria.

25 h potential relevance in chronic spontaneous urticaria.

26 en made for patients with chronic idiopathic urticaria.

27 urticaria, contact urticaria, and aquagenic urticaria.

28 bratory angioedema and aquagenic and contact urticaria.

29 It encompasses spontaneous and inducible urticarias.

30 cne vulgaris, 0.19% for psoriasis, 0.19% for urticaria, 0.16% for viral skin diseases, 0.15% for fung

31 showed a higher point prevalence of chronic urticaria (1.4%, 95%-CI 0.5-2.9) than those from Europe

32 laxis, 84.0 (SD 13.6) in seven patients with urticaria, 142.0 (SD 24.0) in two patients with eczema,

33 iagnosis and management of acute and chronic urticaria: 2014 update." This is a complete and comprehe

34 Among 386 patients diagnosed as spontaneous urticaria, 284 patients (73.6%) had begun treatments wit

35 ort comprised 18 cases of chronic and active urticaria, 7 cases of chronic and inactive urticaria, an

36 phenotypes, all of whom had evaporative cold urticaria, 8 patients had a history of unique neonatal-o

37 C-reactive protein correlated with urticaria activity (P < .001), quality of life impairmen

38 The clinical features studied included: urticaria activity and impact (UAS7 and quality of life)

39 The urticaria activity score (UAS) is the gold standard for

40 UAS7, weekly total values of the Urticaria Activity Score (UAS), has correlation with Der

41 aningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5

42 defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] </= 6) or complete respo

43 on with disease activity, as assessed by the urticaria activity score and with reduced basophil count

44 sponse after retreatment was assessed by the urticaria activity score in patients with chronic sponta

45 s of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) 6: 51.9% vs.

46 mplete response, were assessed by use of the urticaria activity score, physician and patient visual a

47 iable tool to assess disease activity is the Urticaria Activity Score, which prospectively documents

48 te-to-severe disease activity as reported by Urticaria Activity Score.

49 Efficacy (itch severity, hive, and urticaria activity scores) was evaluated at weeks 12 and

50 (P=.001), and those who experienced isolated urticaria after NSAID intake (P=.024).

51 ued because of a drug-related adverse event (urticaria) after week 24.

52 azard ratio [aHR], 2.49; 95% CI, 1.93-3.21), urticaria (aHR, 1.32; 95% CI, 1.00-1.74), or asthma (aHR

53 Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of chronic spo

54 eport on physical urticarias and cholinergic urticaria (Allergy, 2009).

55 Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do

56 Urticaria, anaphylactic reaction, and angioneurotic edem

57 zed disinfectant that can cause IgE-mediated urticaria/anaphylaxis.

58 ne and levocetirizine in chronic spontaneous urticaria and against histamine-induced weal and flare r

59 IgE-mediated reactions (urticaria and anaphylaxis) were seen in 15%.

60 for the management of patients with chronic urticaria and angioedema has been prepared by the Standa

61 Patient-reported data on urticaria and angioedema symptoms, HRQoL, and work produ

62 Urticaria and angioedema were not reported as symptoms i

63 /angioedema (NIUA), and single NSAID-induced urticaria and angioedema.

64 l approach to the patient with NSAID-induced urticaria and angioedema.

65 ere more prevalent among urban participants, urticaria and asIgE sensitization among rural participan

66 atient 2, a 24-year-old woman, was seen with urticaria and associated joint pain and swelling.

67 atient 1, a 47-year-old woman, was seen with urticaria and associated night sweats, fevers, and polya

68 , and chronic inflammatory diseases, such as urticaria and asthma.

69 iseases allergic asthma, chronic spontaneous urticaria and atopic eczema.

70 y score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients

71 nts with clinical features such as vibratory urticaria and dysautonomia.

72 Two developed urticaria and one developed urticaria and dyspnea.

73 nder and Alternaria tenuis with a history of urticaria and dyspnoea after drinking beer and a weak sk

74 E mAb, for patients with chronic spontaneous urticaria and for the clinical benefit of patients with

75 n from patients with confirmed NSAID-induced urticaria and healthy controls, at baseline and at vario

76 identified in individuals with cold-induced urticaria and immune dysregulation PLCG2 exon-skipping m

77 Two developed urticaria and one developed urticaria and dyspnea.

78 Chronic spontaneous urticaria and other chronic forms of urticaria do not on

79 e 2 clinical trials for treatment of chronic urticaria and Sjoegren's syndrome.

80 e 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

81 dance with special sections on children with urticaria and the use of antihistamines in women who are

82 he skin of patients with chronic spontaneous urticaria and was released from isolated basophils follo

83 aminergic angioedema generally presents with urticaria and/or pruritus and will respond to convention

84 te our previous consensus report on physical urticarias and cholinergic urticaria (Allergy, 2009).

85 e urticaria, 7 cases of chronic and inactive urticaria, and 7 cases of acute urticaria.

86 y angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria.

87 Additionally, contact dermatitis, urticaria, and drug reactions are addressed in this revi

88 Urticaria, and especially chronic spontaneous urticaria

89 previously unreported mediator in vibratory urticaria, and extracellular signal-regulated kinases 1/

90 of biologics to manage uncontrolled asthma, urticaria, and nasal polyposis.

91 trongest for symptomatic dermographism, cold urticaria, and solar urticaria.

92 Many notable advances in drug allergy, urticaria, angioedema, and anaphylaxis were reported in

93 Novel pathogenic insights, for example, into urticaria, angioedema, mastocytosis, led to the developm

94 he most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), re

95 Multiple NSAID-induced urticaria/angioedema (MNSAID-UA) is an entity well diffe

96 persensitivity reactions, with NSAID-induced urticaria/angioedema (NIUA) being the most frequent clin

97 of drug hypersensitivity with NSAIDs-induced urticaria/angioedema (NIUA) the most common phenotype.

98 nonsteroidal anti-inflammatory drug-induced urticaria/angioedema (NIUA), and single NSAID-induced ur

99 Nonsteroidal anti-inflammatory drugs-induced urticaria/angioedema does not seem to precede the onset

100 The absence of urticaria/angioedema during sting-induced anaphylaxis is

101 Absence of urticaria/angioedema is an indicator of severe anaphylax

102 The absence of urticaria/angioedema is significantly related to BST ele

103 patients with NECD and single-NSAID-induced urticaria/angioedema or anaphylaxis (SNIUAA) for compari

104 (ii) patients with more than two episodes of urticaria/angioedema to a single NSAID with good toleran

105 : initial reaction characteristics (isolated urticaria/angioedema vs other presentations), baseline e

106 Among patients with urticaria/angioedema, 13 patients (3.9%) had a history o

107 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmedi

108 antibodies to the drug (single NSAID-induced urticaria/angioedema, SNIUA), and (iii) controls who tol

109 ting nonimmediate maculopapular exanthema or urticaria/angioedema.

110 erbated cutaneous disease and NSAIDs-induced urticaria/angioedema.

111 ll into the second one: single-NSAID-induced urticaria/angioedema/anaphylaxis and single-NSAID-induce

112 raoral discomfort, respiratory distress, and urticaria appeared throughout the body.

113 east a subset of cases of chronic idiopathic urticaria are autoimmune in origin.

114 dermatitis, allergic contact dermatitis, and urticaria are very common.

115 n inflammation, such as atopic dermatitis or urticaria, are poorly defined.

116 els (P = .03) but only rarely had angioedema/urticaria associated with hypotension (P = .004).

117 ome was occurrence of at least 1 AM (eczema, urticaria, asthma, and rhinoconjunctivitis).

118 s anaphylaxis, food allergy, rhinitis, itch, urticaria, atopic dermatitis, and asthma.

119 uate and summarize the prevalence of chronic urticaria by evaluating population-based studies worldwi

120 ommend assessing disease activity in chronic urticaria by using UAS.

121 atopic eczema, skin dryness, psoriasis, and urticaria, can elicit pruritus.

122 Cold contact urticaria (CCU) is characterized by itchy wheal and flar

123 ColdU) is a common form of chronic inducible urticaria characterized by the development of wheals, an

124 74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who show

125 Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often

126 iagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous

127 s lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H1-antihistami

128 patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) trea

129 nic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often continue to experience symptom

130 patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -a

131 ith chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1

132 Several treatment options for cold urticaria (ColdU) have been studied and reported, but sy

133 Cold urticaria (ColdU) is a common form of chronic inducible

134 The reported rate of urticaria comorbidity in PI patients in 18 independent s

135 urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria.

136 any assessment and for the key outcome, the urticaria control test (UCT) score, respectively, and pa

137 etrospectively assess urticaria control, the Urticaria Control Test (UCT).

138 outcome instrument to retrospectively assess urticaria control, the Urticaria Control Test (UCT).

139 urticaria was defined as 'chronic persistent urticaria' (CPU), while the presence of urticaria for 2-

140 ays a week was defined as 'chronic recurrent urticaria' (CRU).

141 ng weals in chronic spontaneous (idiopathic) urticaria (CSU) are incompletely understood.

142 Patients with chronic spontaneous urticaria (CSU) are widely held to often have other auto

143 Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat,

144 an important subtype of chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies t

145 Chronic spontaneous urticaria (CSU) is a common skin disorder, but its clini

146 Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease chara

147 Chronic spontaneous urticaria (CSU) is defined as persistent wheals, angioed

148 Chronic spontaneous urticaria (CSU) is one of the most costly allergic condi

149 Chronic spontaneous urticaria (CSU) is the recurrence of urticaria without a

150 Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with oma

151 quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to h

152 The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical char

153 Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL),

154 Chronic spontaneous urticaria (CSU) significantly impacts the quality of lif

155 levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms.

156 iopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab.

157 fective in patients with chronic spontaneous urticaria (CSU), including severe and treatment-refracto

158 rticaria, and especially chronic spontaneous urticaria (CSU), is a difficult condition to treat.

159 nts given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers,

160 -tolerated treatment for chronic spontaneous urticaria (CSU).

161 tients with a history of chronic spontaneous urticaria (CSU).

162 thogenesis of autoimmune chronic spontaneous urticaria (CSU).

163 safety of omalizumab for chronic spontaneous urticaria (CSU).

164 o in 34 subjects without chronic spontaneous urticaria (CSU).

165 consistently reported in chronic spontaneous urticaria (CSU).

166 ctivity in patients with chronic spontaneous urticaria (CSU).

167 er and are classified as chronic spontaneous urticaria (CSU).

168 with severity scores in chronic spontaneous urticaria (CSU); however, the role of filaggrin breakdow

169 Chronic urticaria (CU) affects 0.1% to 0.3% of children.

170 f NIUA has been suggested to lead to chronic urticaria (CU) in an important proportion of patients, s

171 Chronic urticaria (CU) is a common disease in which most cases w

172 Chronic urticaria (CU) is a disease characterized by pruritic we

173 Chronic urticaria (CU) is a frequent skin disease characterized

174 Chronic urticaria (CU) is a widespread skin disease, characteriz

175 Functional autoantibodies in chronic urticaria (CU) patient sera have been demonstrated again

176 pact on the quality of life (QoL) of chronic urticaria (CU) patients is limited.

177 those of other diseases, such as asthma and urticaria, current data suggest that its diagnosis is of

178 dU subtypes: symptomatic dermographism, cold urticaria, delayed-pressure urticaria, solar urticaria,

179 the 4-item UCT in 120 patients with chronic urticaria demonstrated that this new tool exhibits good

180 For children with chronic urticaria, determination of NSAID hypersensitivity in a

181 taneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of lif

182 c urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-anti

183 g of erythritol induced remarkable coughing, urticaria, edema, wheezing and hypoxemia.

184 lysis, has been found to be increased during urticaria exacerbations; moreover, it has been proposed

185 on adverse events included infections, rash, urticaria, fatigue, and pruritus.

186 diators from MCs and, in many cases, such as urticaria, flushing, angioedema, and anaphylaxis, are an

187 tent urticaria' (CPU), while the presence of urticaria for 2-4 days a week was defined as 'chronic re

188 ectively documents the signs and symptoms of urticaria for several days.

189 d the patients who suffered from spontaneous urticaria for six weeks or longer at their first visit t

190 nic spontaneous urticaria (without inducible urticaria) for >2 months are reported here.

191 igher than those in the chronic and inactive urticaria group (p<0.01).

192 PTF1+2 levels in the acute urticaria group were higher than those in the chronic an

193 PTF1+2 levels in the chronic and active urticaria group were higher than those in the chronic an

194 paths forward in patients with drug allergy, urticaria, HAE, and anaphylaxis.

195 coagulation dysfunction and the pathology of urticaria has been reported, but research in children is

196 Chronic spontaneous urticaria has considerable humanistic and economic impac

197 Patients with autosomal dominant vibratory urticaria have localized hives and systemic manifestatio

198 urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, choline

199 of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema withou

200 Prognosis of spontaneous urticaria in association with early treatment remained u

201 for the management of patients with chronic urticaria in clinical practice.

202 ts who are seen with antihistamine-resistant urticaria in combination with systemic inflammatory symp

203 no standard for assessing pediatric chronic urticaria in Japan.

204 cal symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despi

205 y studied the prognosis of acute spontaneous urticaria in relation to age and treatments in a local c

206 One case of urticaria in the vaccine group and one each of acute gas

207 onymous variant cosegregating with vibratory urticaria in two large kindreds.

208 asthma and/or atopy (hay fever and/or eczema/urticaria) in a historical cohort of students born befor

209 Urticaria including CSU is more prevalent in patients wi

210 Urticaria including CSU might be a quite common symptom

211 anagement approaches to treatment of chronic urticaria, including use of omalizumab, are being identi

212 Chronic urticaria is a common disorder characterized by recurren

213 Chronic urticaria is a frequent and debilitating skin disease.

214 Urticaria is a frequent skin condition, but reliable pre

215 Urticaria is a frequent, mast cell-driven disease, prese

216 The life-time prevalence for acute urticaria is approximately 20%.

217 An autoimmune subset of chronic spontaneous urticaria is increasingly being recognized international

218 n association with mastocytosis, asthma, and urticaria, is used in conjunction with stem cell factor

219 re persistent asthma and chronic spontaneous urticaria, major efforts have been undertaken to develop

220 Chronic spontaneous urticaria markedly interfered with sleep and daily activ

221 t clinical problem in the context of chronic urticaria (mast cell mediator-induced), ACE-inhibitor in

222 toimmune disorders, type 2 diabetes, chronic urticaria, mastocytosis, and cancer.

223 Patients with chronic urticaria more frequently had seropositivity of fasciolo

224 e in other indications such as acquired cold urticaria, mosquito bite allergy and mastocytosis.

225 Thirty-one patients (20%) had inducible urticaria, most commonly cold induced.

226 Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asth

227 c IgE to Na-ASP-2 that result in generalized urticaria on vaccination with recombinant Na-ASP-2.

228 ely event such as acute asthma exacerbation, urticaria or anaphylaxis, or an exacerbation of allergic

229 .001): (1) elevation of BST, (2) absence of urticaria or angioedema during anaphylaxis, (3) time int

230 The absence of urticaria or angioedema in severe reactions to Hymenopte

231 Some patients who achieved well-controlled urticaria or complete response sustained response throug

232 angioedema patients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked

233 A moderate-risk history includes urticaria or other pruritic rashes and reactions with fe

234 ger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a careful

235 skin reactions manifesting with angioedema, urticaria, or both have been distinguished: NSAID-exacer

236 nic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omali

237 n patients with cholinergic urticaria, solar urticaria, or pressure urticaria).

238 ndicated an increasing prevalence of chronic urticaria over time.

239 World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective,

240 Chronic spontaneous urticaria patients (18-75 years) were randomized to eith

241 ed MC in normal neck skin in anaphylaxis and urticaria patients with elevated sBT.

242 UAS7 values reflected chronic urticaria patients' quality of life impairment.

243 e in UAS7 values reflected change in chronic urticaria patients' quality of life impairment.

244 kin samples derived from chronic spontaneous urticaria patients.

245 on of ISM without accompanying skin lesions [urticaria pigmentosa (UP)] are lacking.

246 cell infiltration-related symptoms including urticaria pigmentosa and organomegaly (P < .02).

247 differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P

248 ween patients with and without osteoporosis, urticaria pigmentosa or anaphylaxis, respectively (P < 0

249 the typical maculopapular cutaneous lesions (urticaria pigmentosa) should be subdivided into 2 varian

250 gen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol intake are easy to col

251 e), low hip bone mineral density, absence of urticaria pigmentosa, and alcohol intake at the time of

252 phylaxis, documented hypotension, absence of urticaria pigmentosa, and normal SBT levels.

253 son, acne vulgaris, bacterial skin diseases, urticaria, pruritus, scabies, cellulitis, and alopecia a

254 umab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire.

255 ) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1

256 elated with sizes of SPT (erythema: r=0.645, urticaria: r=0.657).

257 active capacity of CU sera was evaluated and urticaria-related symptoms were assessed by both UCT and

258 Chronic urticaria resolved in 43 patients, with a rate of resolu

259 d clinical allergy-related outcomes (wheeze, urticaria, rhinitis and visible flexural dermatitis), an

260 The most frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough.

261 pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, absc

262 is with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting ty

263 On a global level, the prevalence of chronic urticaria showed considerable regional differences.

264 mographism, cold urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory an

265 rmined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria).

266 were conducted of outpatients treated at an urticaria specialist center of a university hospital.

267 ess disease control in patients with chronic urticaria (spontaneous and inducible).

268 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained s

269 children and adolescents, different chronic urticaria subtypes and potential risk and protective fac

270 t is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab t

271 covers the definition and classification of urticaria, taking into account the recent progress in id

272 We followed a pediatric cohort with chronic urticaria that presented with hives lasting at least 6 w

273 However, the non-remission rate of urticaria that was treated with a standard dose of antih

274 ion typically involves the skin (generalized urticaria), the respiratory tract (cough, wheeze, strido

275 ingestion of mammalian meat and ranged from urticaria to anaphylaxis.

276 up-dosing was without sedation and supports urticaria treatment guidelines.

277 rrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening to

278 ses that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as

279 recurrent anaphylaxis, angioedema, or acute urticaria underwent spirometry, exhaled nitric oxide, qu

280 Forty-four patients with anaphylaxis or urticaria upon CHX exposure and positive skin prick test

281 g allergies, eczema, food allergy, rhinitis, urticaria, venom allergy and other probable allergic dis

282 ed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria,

283 Duration of chronic urticaria was 5.5 months.

284 or almost daily (>4 days a week) presence of urticaria was defined as 'chronic persistent urticaria'

285 Urticaria was observed in QGE031- and placebo-treated su

286 for a potential vaccination-related symptom (urticaria) was reported.

287 ld or younger by one year after the onset of urticaria, was significantly lower than that of patients

288 d angioedema does not typically present with urticaria/weals and does not respond to conventional age

289 Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] </= 6)

290 linical records of patients with spontaneous urticaria were extracted.

291 r hospital because of repetitive episodes of urticaria when she consumed pork meat.

292 inflammatory skin diseases including chronic urticaria which is associated by increased IL-31 serum l

293 effective and safe in patients with chronic urticaria who have benefited from initial omalizumab tre

294 s with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite H-antihistami

295 screening accuracy to identify patients with urticaria with insufficiently controlled disease was fou

296 t encountered anaphylaxis with one NSAID and urticaria with other NSAIDs, and the last patient had an

297 We describe 2 patients having neutrophilic urticaria with systemic inflammation (NUSI) without know

298 us tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

299 taneous urticaria (CSU) is the recurrence of urticaria without an apparent trigger.

300 antihistamine-refractory chronic spontaneous urticaria (without inducible urticaria) for >2 months ar